2-methyl-N-ethylpiperidine | 766-52-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-methyl-N-ethylpiperidine
• 英文别名: 1-ethyl-2-methyl-piperidine；(+/-)-1-Aethyl-2-methyl-piperidin；1-Aethyl-2-methyl-piperidin；1-Ethyl-2-methyl-piperidin；1-Ethyl-2-methylpiperidin；1-Ethyl-2-methylpiperidine
• CAS: 766-52-9
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: LPCWDBCEHWHJGX-UHFFFAOYSA-N

物化性质

• 保留指数：
  923

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-methyl-N-ethylpiperidine 、 碘甲烷 在 potassium hydrogencarbonate 作用下， 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  Guest/Host Relationships in the Synthesis of the Novel Cage-Based Zeolites SSZ-35, SSZ-36, and SSZ-39

  摘要：

  Here, we report the synthesis and structure of three high-silica molecular sieves, SSZ-35, SSZ-36, and SSZ-39, that are prepared from a library of 37 different cyclic and polycyclic quaternized amine molecules that are used as structure-directing agents (SDAs). The size and shape of the quaternized amine molecules are purposely designed in order to obtain novel zeolite structures, and the synthesis of these molecules is presented. The selectivity for the three molecular sieve phases is found to depend on both the SDA and the degree of heteroatom lattice substitution of Al3+ or B3+ in the silicate framework. Molecular modeling is utilized to probe the effects of the nonbonded SDA/zeolite-framework interaction energy on the selectivity for the observed molecular sieve phase. The Rietveld refinement of the powder X-ray data confirms the structure of the SSZ-39 zeolite to be isomorphous with the aluminophosphate molecular sieve, SAPO-LS (AEI). The structure of SSZ-36 is found to possess a range of fault probabilities between the two-dimensional channel system, end-member polymorphs, ITQ-3 and RUB-13 (International Zeolite Association Codes ITE and RTH, respectively). The SSZ-35 structure is reported to contain a one-dimensional pore system possessing stacked cages circumscribed by alternating rings of 10 and 18 tetrahedral atoms (10- and 18-membered rings).

  DOI：

  10.1021/ja990722u
• 作为产物：
  描述：

  6-溴-2-己酮 在 盐酸 、 tin 作用下， 生成 2-methyl-N-ethylpiperidine
  参考文献：
  名称：

  Ladenburg; Kruegel, Justus Liebigs Annalen der Chemie, 1899, vol. 304, p. 56

  摘要：

  DOI：

文献信息

• Alpha-Ketoamide Inhibitors Of Cysteine Proteases
  申请人：Phelix Therapeutics

  公开号：US20190085024A1

  公开（公告）日：2019-03-21

  The disclosure provides compounds comprising a α-ketoamide linkage that is terminated on each end by an amino acid, such as compounds of Formula (I), wherein RA-RC are defined herein. Also provided are compositions containing these compounds and methods of inhibiting calpain activity, treating a calpain-mediated disorder, inhibiting cathepsin-B, cathepsin-L, cathepsin-S, or cathepsin-L activity, and methods of treating a cathepsin-B, cathepsin-L, cathepsin-S, or cathepsin-L mediated disorder using these compounds and compositions.

  该披露提供了包含α-酮酰胺键的化合物，该键在每端由氨基酸终止，例如式(I)中的化合物，其中RA-RC在此处定义。还提供了含有这些化合物的组合物以及抑制钙蛋白酶活性、治疗钙蛋白酶介导的疾病、抑制卡托普西-B、卡托普西-L、卡托普西-S或卡托普西-L活性的方法，以及使用这些化合物和组合物治疗卡托普西-B、卡托普西-L、卡托普西-S或卡托普西-L介导的疾病的方法。
• HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Asana Biosciences, LLC

  公开号：US20160362407A1

  公开（公告）日：2016-12-15

  The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R 1 to R 8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新颖的杂环化合物及其药用可接受的盐。还提供了制备这些化合物的方法。这些化合物对抑制ERK1/2有用。通过向需要治疗的患者施用式(I)的一个或多个化合物的治疗有效量，其中X、Y、Z、J、M和R1至R8在此处定义，这些化合物在治疗与RAS/RAF/MEK/ERK通路失调相关的疾病方面是有效的。可以使用这些化合物治疗各种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。
• Pyrrolidine and related derivatives useful as PR modulators
  申请人：Commons Thomas Joseph

  公开号：US20080045560A1

  公开（公告）日：2008-02-21

  Compounds of the following structure are described: wherein R 1 -R 6 , R 11 , R 12 , m, V, X, Y, Z and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

  以下结构的化合物被描述如下： 其中R1-R6，R11，R12，m，V，X，Y，Z和Q在此处描述，或其药学上可接受的盐、异构体、代谢物或前药。这些化合物可用于治疗各种激素相关疾病，包括避孕、治疗或预防子宫肌瘤、子宫内膜异位症、功能性出血、子宫平滑肌瘤、多囊卵巢综合征、激素依赖性癌症、提供激素替代疗法、促进食欲或同步发情。
• Tricyclic oxazolidone derivatives useful as PR modulators
  申请人：Commons Thomas Joseph

  公开号：US20080045578A1

  公开（公告）日：2008-02-21

  Compounds of the following structure are described: wherein R 1 -R 6 , R 16 , m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

  以下结构的化合物被描述如下： 其中R1-R6，R16，m，V，W，X，Y和Q在此处描述，或其药学上可接受的盐，异构体，代谢物或前药。这些化合物可用于治疗各种激素相关疾病，包括避孕，治疗或预防子宫肌瘤，子宫内膜异位症，功能性出血，子宫平滑肌瘤，多囊卵巢综合征，或激素依赖性癌症，提供激素替代疗法，刺激食欲或同步发情。
• Cyanopyrrole-phenyl progesterone receptor modulators and uses thereof
  申请人：McComas Cameron Casey

  公开号：US20070027125A1

  公开（公告）日：2007-02-01

  Progesterone receptor modulators of formula I, or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined herein. These compounds are useful for contraception and hormone replacement therapy. Also provided are products containing these compounds.

  公式I的孕酮受体调节剂，或其药用盐， 其中R1，R2，R3，R4，R5，R6和R7如本文所定义。这些化合物对避孕和激素替代疗法有用。还提供含有这些化合物的产品。

表征谱图